Overview
What Akina Pharmacy does: It provides specialty compounding medications—both sterile and non-sterile—tailored to individual patient needs for healthcare providers and patients, with a focus on exceptional service. How its products work: Pharmacists prepare customized medications based on doctors’ prescriptions, ensuring meticulous accuracy, sterility, and proper formulation so the medicine fits the patient’s specific health situation and timeline. How it differs from competitors: The pharmacy emphasizes precise, personalized compounding and high-quality service, aiming to deliver the right medication in the right place at the right time for the right person, with a patient-centered approach. What its goal is: To enrich lives through personalized medicine and care, doing the right thing in the right way, at the right time, for the right person, with the right feeling, the first time.
Work here?Claim your company
Simplify's Take
What believers are saying
- October 2025 atropine launch targets pediatric myopia, a high-growth specialty niche.
- Akina updated hormone therapy materials after November 2025 FDA labeling guidance, showing responsiveness.
- Website updates in 2026 and AI partnership messaging signal active commercial execution.
What critics are saying
- FDA listed Akina as a 503A facility with a 2024 warning letter.
- Compounded drugs face non-approval scrutiny and replication limits from FDA regulations.
- A small 21-to-50 employee base concentrates operational risk if inspections or recalls escalate.
What makes Akina Pharmacy unique
- 503A compounding pharmacy serving patient-specific prescriptions, not mass-market drugs.
- Launches preservative-free low-dose atropine for pediatric myopia with PureFlow bottle technology.
- Broad specialty mix and rapid insurance handling differentiate Akina in physician workflows.
Help us improve and share your feedback! Did you find this helpful?